Centene stock
CNCNYSECentene Corp., HealthcareISIN US15135B1017
54Score 54 out of 100, Neutral
Price and trend
82 / 100
Price history
+99% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 25% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 7.3% below its 52-week high. Largest decline in 20 years: 74% (August 2022 to August 2025).
Chart figures for advanced users
- SMA 50$66.95
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$56.35
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$31.80
- The lowest closing price of the last twelve months.
- Resistance$76.01
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Centene Corp. belongs to the Medical (Healthcare Plans) industry (United States) and, with a market value of $34.89B, is number 6 of 12 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $194.78B (up 19.4% year on year) and a loss of $6.67B.
- For fiscal 2026, analysts expect on average revenue of $200.21B (up 2.8%) and adjusted earnings per share of $5.26 (up 156.7%).
Show more
- MEQIRI Score 54 out of 100 (Neutral): rank 343 of 714 in Healthcare, median 53.
- The P/E is 23.8 (Medical (Healthcare Plans) median 23, own median of recent years 19.7).
- Our model puts fair value at $119.16, with the price 41% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 271% of earnings over the last 12 months.Fundamentals 67
- Below fair valuePrice 41% below the fair value of $119.16.Valuation 78
- Share buybacksShare count down 14% since 2020.
Weaknesses
- Turned to a lossEarnings per share from $3.17 in 2020 to −$13.61.Growth 45
- Volatile share priceVolatility 46% a year over the last 12 months.Stability 41
Its standout strengths are momentum and technical analysis, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 55 to 54.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high price swings
- price up very strongly over the past year
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $85.12 and expensive above $198.60 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $170.29 (cash-flow model) and $68.03 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $106.10, at 7.8% it would be $138.67.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (23).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 9.7% on the twelve months before. Revenue has grown strongly since 2006, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 12%, operating −4%, net −3%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 5 Feb 2027in 85 days
- Last reported
- 27 Oct 2026EPS reported $0.58 (expected $0.10)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 8.0% since 15 Oct 2026.
- Earnings per share
- $5.26+8.0%
- Revenue
- $200.21B+2.0%
- Earnings per share
- $5.53+4.3%
- Revenue
- $195.15B+1.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −1.4%Centene raised its full-year 2026 adjusted EPS guidance to more than $5.20 and improved its margin outlook for PDP (mid to high 3%) and Marketplace (top of 4.5% to 5.0% range).
“We ended Q3 with 11.9 million members down 5.0% year to date and we expect some states to continue to trim Medicaid roles leading up to OB3 implementation in 2027 So we are holding our full-year view of membership down 8% to 9%, along with the 2026 forecasted 93.5% HBR.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 27 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $12.06M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Centene
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 54
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Plans)
The next larger and next smaller companies by market value
- CVS HealthCVS $114.54B60
- Elevance HealthELV $92.79B69
- CignaCI $79.43B66
- HumanaHUM $53.6B63
- Molina HealthcareMOH $10.92B50
- Oscar HealthOSCR $9.93B71
- BradsaudeSAUD3.SA $8.69B80
- ProgynyPGNY $2.69B79
ETFs that hold Centene
Held by 129 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Invesco Global Active ESG Equity UCITS ETF USD AccIQSA | 1.50% | 0.30% | €3.12B |
| iShares Edge MSCI USA Value Factor UCITS ETFQDVI | 0.57% | 0.20% | €2.9B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.55% | 0.15% | €592.11M |
Show 5 more
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.55% | 0.15% | €3.27B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.55% | 0.12% | €1.34B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.43% | 0.18% | €837.43M |
| State Street SPDR MSCI USA Value UCITS ETF USD AccZPRU | 0.43% | 0.20% | €294.97M |
| Goldman Sachs ActiveBeta Paris-Aligned Sustainable US Large Cap Equity UCITS ETFGACA | 0.41% | 0.14% | €135.41M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 9 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.